Sign in

EXELIXIS (EXEL)

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for EXELIXIS.

Q3 2026

→

Q2 2026

→

Q1 2026

→

Q4 2025

→

Executives

Executive leadership at EXELIXIS.

Michael M. Morrissey

Detailed

President and Chief Executive Officer

CEO

Brenda Hefti

Detailed

General Counsel

Christopher J. Senner

Detailed

Executive Vice President and Chief Financial Officer

Dana T. Aftab

Detailed

Executive Vice President, Research and Development

Patrick J. Haley

Detailed

Executive Vice President, Commercial

Board Members

Board of directors at EXELIXIS.

David E. Johnson

Detailed

Independent Director

George Poste

Detailed

Independent Director

Jack L. Wyszomierski

Detailed

Independent Director

Julie Anne Smith

Detailed

Independent Director

Maria C. Freire

Detailed

Independent Director

Mary C. Beckerle

Detailed

Independent Director

Robert L. Oliver, Jr.

Detailed

Independent Director

S. Gail Eckhardt

Detailed

Independent Director

Stelios Papadopoulos

Detailed

Independent Chair of the Board

Tomas J. Heyman

Detailed

Independent Director

Analyst Coverage

Research analysts who have asked questions during EXELIXIS earnings calls.

Asthika Goonewardene

Truist Securities

6 questions for EXEL

Also covers: ALLO, AUTL, BNTX +9 more

Michael Schmidt

Guggenheim Securities

6 questions for EXEL

Also covers: ADAP, ADCT, ARVN +19 more

Ashwani Verma

UBS Group AG

5 questions for EXEL

Also covers: ACAD, ALKS, ALVO +12 more

Jason Gerberry

Bank of America Merrill Lynch

4 questions for EXEL

Also covers: ALKS, AMPH, ARWR +21 more

Peter Lawson

Barclays PLC

4 questions for EXEL

Also covers: ADAP, ARVN, BPMC +15 more

Sudan Loganathan

Stephens Inc.

4 questions for EXEL

Also covers: ADCT, ARVN, BPMC +6 more

Yaron Werber

TD Cowen

4 questions for EXEL

Also covers: ALEC, AMGN, ARGX +14 more

Akash Tewari

Jefferies

3 questions for EXEL

Also covers: ALKS, APLS, ARGX +15 more

Anastasia Parafestas

Jefferies

3 questions for EXEL

Also covers: ALKS

David Lebowitz

Citigroup Inc.

3 questions for EXEL

Also covers: ALNY, ARWR, ASND +11 more

Gregory Renza

RBC Capital Markets

3 questions for EXEL

Also covers: ACAD, ADCT, AGIO +12 more

Sean Laaman

Morgan Stanley & Co.

3 questions for EXEL

Also covers: ACAD, ARGX, AXSM +8 more

Silvan Tuerkcan

Citizens JMP

3 questions for EXEL

Also covers: CLLS, MGNX, NTLA +2 more

Stephen Willey

Stifel Financial Corp.

3 questions for EXEL

Also covers: ABCL, CELC, CGEN +10 more

Andrew Berens

Leerink Partners

2 questions for EXEL

Also covers: AGIO, ARVN, BGNE +6 more

Andy Shea

William Blair

2 questions for EXEL

Chi Meng Fong

BofA Securities

2 questions for EXEL

Also covers: BHC, BYSI, GUTS +2 more

Christopher Lu

SVB Leerink

2 questions for EXEL

Also covers: HOOK

Derek Archila

Wells Fargo

2 questions for EXEL

Also covers: APLS, ARGX, ARVN +9 more

Karishma Raghuram

Goldman Sachs

2 questions for EXEL

Also covers: ALKS, RVNC

Katherine

Morgan Stanley

2 questions for EXEL

Leonid Timashev

RBC Capital Markets

2 questions for EXEL

Also covers: ADCT, ALKS, AXSM +8 more

Sarah

TD Cowen

2 questions for EXEL

Sean

Oppenheimer & Co. Inc.

2 questions for EXEL

Silvan Turkin

Citizens

2 questions for EXEL

Stephen Willey

Stifel

2 questions for EXEL

Also covers: ABCL, ABEO, CGEN +7 more

Tsan-Yu Hsieh

William Blair & Company

2 questions for EXEL

Also covers: AVIR, CRDF, FGEN +6 more

Andy Hsieh

William Blair & Company

1 question for EXEL

Also covers: ALT, BYSI, CRDF +8 more

Andy Shah

William Blair & Company

1 question for EXEL

Also covers: ALT, CRDF

Anish Nikhanj

RBC Capital Markets

1 question for EXEL

Also covers: APTO, CRMD, FULC +6 more

Ash Verma

UBS

1 question for EXEL

Also covers: ALVO, AVDL, INCY +5 more

Cheng Li

Oppenheimer & Co. Inc.

1 question for EXEL

Also covers: EDIT, INO, NKTR +3 more

Chris Shibutani

Goldman Sachs Group, Inc.

1 question for EXEL

Also covers: ABBV, ALKS, BMY +11 more

Etzer Darout

BMO Capital Markets

1 question for EXEL

Also covers: ARVN, CTMX, GMAB +5 more

Eva Fortea-Verdejo

Wells Fargo Securities

1 question for EXEL

Also covers: KNSA, KYMR, RCUS

Jay Olson

Oppenheimer & Co. Inc.

1 question for EXEL

Also covers: ACAD, AMGN, BIIB +22 more

Joseph Catanzaro

Wolfe Research, LLC

1 question for EXEL

Also covers: AADI, CPRX, CRDF +7 more

Sudan Loganison

Stephens

1 question for EXEL

Latest news

Recent press releases and 8-K filings for EXEL.

Exelixis Reports Strong Q3 2025 Results and Advances Key Pipeline Products
EXEL
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
  • Exelixis reported strong Q3 2025 financial results, with $543 million in net product revenue and total revenues just under $600 million, largely due to the success of Cabometyx.
  • The launch of Cabometyx in neuroendocrine tumors (NET) is performing strongly, showing 50% quarter-over-quarter growth and achieving over 40% market share in new patient starts, with sales expected to surpass $100 million for the year.
  • The company plans to submit an NDA for its key pipeline product, Zanzalintinib (Zanza), in colorectal cancer by the end of 2025, targeting a $1 billion opportunity in the US.
  • Exelixis is also advancing Zanza in other indications, with an upcoming data release for non-clear-cell RCC in H1 2026 and a Phase II/III study in neuroendocrine tumors, aiming to build new oncology franchises.
Nov 10, 2025, 3:30 PM
Transcript
Exelixis Reports Strong Q3 2025 Results and Pipeline Progress
EXEL
Earnings
Product Launch
New Projects/Investments
  • Exelixis reported strong Q3 2025 financial performance, with net product revenue of $543 million and total revenues just under $600 million.
  • The Cabometyx launch for neuroendocrine tumors (NET) is exceeding expectations, showing 50% quarter-over-quarter growth and capturing over 40% market share in new patient starts, with projected incremental full-year sales exceeding $100 million.
  • The company is advancing its pipeline with a planned NDA submission for Zanzalintinib (Zanza) by end of 2025 for colorectal cancer, and is exploring its potential in non-clear-cell renal cell carcinoma (RCC) and in combination with Merck's Belzutifan for RCC.
Nov 10, 2025, 3:30 PM
Transcript
Exelixis Discusses Strong Q3 2025 Performance and Pipeline Progress
EXEL
Earnings
Product Launch
New Projects/Investments
  • Exelixis reported strong Q3 2025 financial results, with $543 million in net product revenue and total revenues just under $600 million.
  • The launch of Cabometyx in neuroendocrine tumors (NET) is performing well, achieving 50% Q over Q growth and over 40% market share in new patient starts, with full-year sales projected to exceed $100 million.
  • Zanzalintinib (Zanza) is a key pipeline asset with an NDA submission planned by year-end, targeting a $1 billion opportunity in the US for colorectal cancer (CRC).
  • Further opportunities for Zanza include upcoming data in non-clear-cell RCC in the first half of next year, which accounts for 15%-20% of the overall RCC population, and a partnership with Merck for a combination in RCC.
  • The company is strategically expanding its commercial footprint, particularly in the GI space, to support current and future product launches.
Nov 10, 2025, 3:30 PM
Transcript
Exelixis Reports Strong Q3 2025 Results, Cabozantinib Growth, and Positive Zanzalintinib Trial Data
EXEL
Earnings
Guidance Update
Share Buyback
  • Exelixis reported Q3 2025 total revenues of $598 million and GAAP diluted earnings per share (EPS) of $0.69, with non-GAAP diluted EPS of $0.78.
  • The Cabozantinib U.S. franchise net product revenues grew approximately 14% year-over-year to $543 million in Q3 2025, and global net product revenues were $739 million. The company expects to exceed $100 million in revenue for the neuroendocrine tumor (NET) indication in 2025.
  • Zanzalintinib (Zanza) showed positive results from the STELLAR-303 trial in colorectal cancer (CRC), demonstrating a 20% reduction in the risk of death in the ITT population, and the company intends to file for regulatory approval based on these results.
  • The company's board authorized an additional $750 million share repurchase program on October 31, 2025, expiring at the end of 2026, following the repurchase of approximately $99 million in Q3 2025.
  • Exelixis updated its full-year 2025 guidance, narrowing total revenue to between $2.3 billion and $2.35 billion and net product revenue to between $2.1 billion and $2.15 billion, while also lowering R&D expense guidance to $850-$900 million.
Nov 4, 2025, 10:00 PM
Transcript
Exelixis Reports Strong Q3 2025 Results, Updates Full-Year Guidance, and Authorizes New Share Repurchase Program
EXEL
Earnings
Guidance Update
Share Buyback
  • Exelixis reported Q3 2025 total revenues of $598 million, with GAAP diluted earnings per share of $0.69 and non-GAAP diluted earnings per share of $0.78.
  • The Cabozantinib franchise saw US net product revenues increase 14% year-over-year to $543 million in Q3 2025, and the neuroendocrine tumor (NET) indication is projected to exceed $100 million in revenue for 2025.
  • Zanzalintinib (Zanza) showed positive results from the Stellar-303 trial in colorectal cancer, demonstrating a 20% reduction in the risk of death in the ITT population, with an NDA filing intended for December.
  • The company updated its full-year 2025 financial guidance, narrowing total revenue to between $2.3 billion and $2.35 billion and net product revenue to between $2.1 billion and $2.15 billion.
  • Exelixis' board authorized an additional $750 million share repurchase program on October 31, 2025, following $99 million in share repurchases during Q3 2025.
Nov 4, 2025, 10:00 PM
Transcript
Exelixis Reports Strong Q3 2025 Results, Updates Full-Year Guidance, and Announces Positive Zanzalintinib Trial Data
EXEL
Earnings
Guidance Update
Share Buyback
  • Exelixis reported Q3 2025 total revenues of $598 million and GAAP diluted EPS of $0.69, with non-GAAP diluted EPS of $0.78.
  • The company updated its full-year 2025 financial guidance, narrowing total revenue to $2.3 billion to $2.35 billion and net product revenue to $2.1 billion to $2.15 billion, both to the upper end of previous guidance. R&D expense guidance was lowered to $850 million to $900 million.
  • Cabozantinib US net product revenues grew 14% year-over-year to $543 million in Q3 2025, contributing to global Cabo franchise net product revenues of $739 million. The neuroendocrine tumor (NET) indication is expected to exceed $100 million in revenue for 2025.
  • Exelixis announced positive results from the Stellar-303 trial for Zanzalintinib in colorectal cancer, demonstrating a 20% reduction in the risk of death in the ITT population, and plans to file an NDA in December 2025, pending government reopening.
  • The board authorized an additional $750 million share repurchase program, following the repurchase of $99 million in Q3 2025.
Nov 4, 2025, 10:00 PM
Transcript
Exelixis Reports Q3 2025 Financial Results, Updates FY 2025 Guidance, and Announces New Stock Repurchase Program
EXEL
Earnings
Guidance Update
Share Buyback
  • Exelixis reported total revenues of $597.8 million and GAAP diluted EPS of $0.69 for the third quarter of 2025, with cabozantinib franchise U.S. net product revenues reaching $542.9 million.
  • The company updated its fiscal year 2025 financial guidance, raising the lower end of total revenues to $2.30 billion - $2.35 billion and net product revenues to $2.10 billion - $2.15 billion. Additionally, research and development expenses guidance was lowered to $850 million - $900 million, and the effective tax rate was updated to 17% - 18%.
  • Exelixis announced an additional stock repurchase program for up to $750 million of its common stock, authorized to be completed by the end of 2026.
  • The company plans to submit its first New Drug Application for zanzalintinib in combination with atezolizumab for advanced colorectal cancer in the U.S. by year-end 2025, following positive STELLAR-303 trial results.
  • Exelixis incurred $19.8 million in restructuring expenses during Q3 2025, primarily due to a corporate reorganization plan involving workforce reorganization and the closure of an office.
Nov 4, 2025, 9:25 PM
8-K
Exelixis Discusses Flagship Product Cabozantinib, Next-Generation Zanzalintinib Development, and R&D Strategy
EXEL
Product Launch
New Projects/Investments
  • Exelixis is a commercial-stage oncology biotech with its flagship molecule, cabozantinib (Cabo), holding seven indications and leading the kidney cancer market.
  • Cabo recently launched a new indication in neuroendocrine tumors (NETs) at the end of Q1, with the launch progressing well despite initial sell-side confusion on expectations.
  • The company is developing zanzalintinib (Zanza), a next-generation molecule, to manage the 2031 patent expiry of Cabo.
  • Zanza's STELLAR-303 trial for colorectal cancer (CRC) achieved a "big win" in the ITT population, with results to be presented at ESMO next month.
  • Exelixis has been profitable for the past seven to eight years and commits approximately $1 billion annually to R&D, focusing on disciplined capital allocation and strategic clinical collaborations to expand its pipeline.
Sep 24, 2025, 12:50 PM
Transcript

Earnings Transcripts

Quarterly earnings call transcripts for EXELIXIS.

Q3 2025

Nov 4, 2025

→

Q2 2025

Jul 28, 2025

→

Q1 2025

May 13, 2025

→
View All Transcripts
Fintool

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Michael M. Morrissey say about margins?What are EXELIXIS's strategic priorities?How is EXELIXIS positioned vs competitors?How did EXELIXIS do last quarter?